Trexquant Investment LP Sells 51,759 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Trexquant Investment LP lowered its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 18.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 227,598 shares of the company’s stock after selling 51,759 shares during the quarter. Trexquant Investment LP owned approximately 0.11% of Cellebrite DI worth $5,014,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. True Wind Capital Management L.P. lifted its position in Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock valued at $305,358,000 after purchasing an additional 2,130,386 shares during the period. Pertento Partners LLP raised its stake in shares of Cellebrite DI by 26.7% during the fourth quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after buying an additional 626,373 shares during the last quarter. Pembroke Management LTD lifted its holdings in Cellebrite DI by 4.4% in the fourth quarter. Pembroke Management LTD now owns 1,992,432 shares of the company’s stock valued at $43,893,000 after buying an additional 84,087 shares during the period. Principal Financial Group Inc. acquired a new stake in Cellebrite DI during the 3rd quarter worth $23,402,000. Finally, Two Sigma Advisers LP raised its position in shares of Cellebrite DI by 9.8% during the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock valued at $22,584,000 after acquiring an additional 120,000 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Finally, Lake Street Capital upped their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI has an average rating of “Buy” and an average price target of $23.43.

Cellebrite DI Stock Down 5.6 %

Shares of CLBT opened at $17.71 on Friday. The stock has a market capitalization of $4.24 billion, a P/E ratio of -12.74, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The company has a 50 day moving average of $20.41 and a 200-day moving average of $19.95.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.